– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries –
Coronary/Structural Heart
RAMPART Announces Collaboration with Armery Medical Technologies to Offer Radial Arm Board Solution
RAMPART, a Birmingham-based medical device company specializing in radiation shielding and orthopedic protection, announced a global collaboration agreement with Armery Medical Technologies to manufacture, sell and distribute the Armery Radial Arm Board solution. The Armery solution maximizes support and protection during radial procedures and furthers Rampart’s mission to provide market […]
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 27, 2024 /PRNewswire/ — Today at the Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics…
ADONA MEDICAL INITIATES FIRST-IN-HUMAN STUDY WITH ITS NOVEL INTERATRIAL SHUNT FOR PATIENTS WITH HEART FAILURE
Initial cases conducted in the Republic of Georgia with support from leading US cardiologists Adjustable interatrial shunt with integrated bi-atrial pressure monitoring aims to deliver a more personalized lifetime approach to heart failure management LOS GATOS, Calif., Oct. 27, 2024…
ADVANCED NANOTHERAPIES ANNOUNCES POSITIVE RESULTS IN ITS FIRST-IN-HUMAN TRIAL AND PLANS FOR U.S. EARLY FEASIBILITY STUDY FOR SIRPLUX™ DUO DRUG-COATED BALLOON
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA CLARA, Calif., Oct. 26, 2024 /PRNewswire/ — Advanced NanoTherapies…
Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today…
Medtronic receives CE Mark for Evolut™ FX+ TAVI system for treatment of symptomatic severe aortic stenosis
Medtronic plc, a global leader in healthcare technology, today announced it has received CE (Conformité Européenne) Mark for the Evolut™ FX+ transcatheter aortic valve implantation (TAVI) system, the company’s latest Evolut TAVI system for the treatment of symptomatic severe aortic stenosis. This follows the recent United States Food and Drug […]
CroíValve Announces First Implant of a Novel Minimally Invasive Device for Tricuspid Regurgitation in US Early Feasibility Study
DUBLIN–(BUSINESS WIRE)–CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of severe+ tricuspid regurgitation (TR), announced the first patient treated with the DUO™ System as part of the TANDEM II Early Feasibility Study in the U.S. The DUO™ System is a […]
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner…
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
BERLIN and BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) — Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019.It leverages Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases.
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet